10-K
Annual Report
60 DEGREES PHARMACEUTICALS, INC.
SXTPW
NASDAQ
CIK: 1946563
File #: 001-41719
Balance Sheet
50 line items · 2 periods
XBRL
| Item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
CONSOLIDATED BALANCE SHEETS | ||
ASSETS: | ||
Current Assets: | ||
Cash and Cash Equivalents | 1,510,065 | 1,659,353 |
Accounts Receivable | 509,644 | 486,748 |
Prepaid and Other Assets | 978,131 | 1,068,940 |
Short-Term Investments | 1,240,721 | 1,728,472 |
Inventory (Note 3) | 656,924 | 442,764 |
Total Current Assets | 4,895,485 | 5,386,277 |
Property and Equipment, net (Note 4) | 246,365 | 149,808 |
Other Assets: | ||
Long-Term Prepaid Expense | 0 | 66,176 |
Intangible Assets, net (Note 5) | 224,361 | 157,084 |
Total Other Assets | 224,361 | 223,260 |
Total Assets | 5,366,211 | 5,759,345 |
LIABILITIES AND SHAREHOLDERS’ EQUITY: | ||
Current Liabilities: | ||
Accounts Payable and Accrued Expenses | 1,459,279 | 1,007,618 |
SBA EIDL (including accrued interest) (Note 7) | 8,772 | 8,772 |
Derivative Liabilities (Note 8) | 374,741 | 640,830 |
Contingent Milestone Payment - Fair Value, Inputs, Level 3 - Fair Value, Recurring | 374,741 | 640,830 |
Derivative Liabilities | 374,741 | 640,830 |
Level 1 - Derivative Liabilities | 0 | 0 |
Level 2 - Derivative Liabilities | 0 | 0 |
Fair Value, Inputs, Level 3 - Derivative Liabilities | 374,741 | 640,830 |
Level 1 | 0 | 0 |
Level 2 | 0 | 0 |
Fair Value, Inputs, Level 3 | 374,741 | 640,830 |
Total Current Liabilities | 1,842,792 | 1,657,220 |
Long-Term Liabilities: | ||
SBA EIDL (including accrued interest) (Note 7) | 144,003 | 147,119 |
Total Long-Term Liabilities | 144,003 | 147,119 |
Total Liabilities | 1,986,795 | 1,804,339 |
SHAREHOLDERS’ EQUITY: | ||
Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 76,480 and 76,480 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively (Note 6) | 9,567,439 | 9,567,439 |
Common Stock, $0.0001 par value, 150,000,000 shares authorized; 1,163,142 and 141,749 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively(1) (Note 6) | 116 | 14 |
Additional Paid-in Capital | 41,646,139 | 34,860,633 |
Accumulated Other Comprehensive Income | 142,598 | 135,471 |
Accumulated Deficit | (47,893,115) | (40,527,957) |
60P Shareholders’ Equity: | 3,463,177 | 4,035,600 |
Noncontrolling Interest | (83,761) | (80,594) |
Total Shareholders’ Equity | 3,379,416 | 3,955,006 |
Series A - Preferred Stock | 9,567,439 | 9,567,439 |
Common Stock | 116 | 14 |
Additional Paid-In Capital | 41,646,139 | 34,860,633 |
Accumulated Deficit | (47,893,115) | (40,527,957) |
Accumulated Other Comprehensive Income (Loss) | 142,598 | 135,471 |
Total Shareholders’ Equity (Deficit) Attributable to 60P | 3,463,177 | 4,035,600 |
Noncontrolling Interest on Shareholders | (83,761) | (80,594) |
Total Liabilities and Shareholders’ Equity | 5,366,211 | 5,759,345 |